Gujarat Magazine

Advanced Cervical Cancer Pipeline Assessment, 2024 Update | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest Approvals, Treatment Outlook, Key Companies

 Breaking News
  • No posts were found

Advanced Cervical Cancer Pipeline Assessment, 2024 Update | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest Approvals, Treatment Outlook, Key Companies

May 22
09:55 2024
Advanced Cervical Cancer Pipeline Assessment, 2024 Update | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest Approvals, Treatment Outlook, Key Companies
Advanced Cervical Cancer Pipeline Insights
As per DelveInsight’s assessment, globally, about 70+ key pharma and biotech companies are working on 75+ pipeline drugs in the Advanced Cervical Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Advanced Cervical Cancer Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Advanced Cervical Cancer Market.

The Advanced Cervical Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Advanced Cervical Cancer Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the emerging therapies for the treatment of Advanced Cervical Cancer and the aggregate therapies developed by major pharma companies.

It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Advanced Cervical Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Route of Administration

Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as –






Molecule Type

Products have been categorized under various Molecule types, such as –

Monoclonal Antibody



Small molecule

Gene therapy

Advanced Cervical Cancer Emerging Therapies Mechanism of Action (MOA) Types:

Programmed cell death-1 receptor antagonists

DNA synthesis inhibitors

Transforming growth factor-beta inhibitors

T lymphocyte replacements

CD4-positive T lymphocyte stimulant

Programmed cell death-1 ligand-1 inhibitor

Antigen-presenting cell modulators


Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development –

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Advanced Cervical Cancer Therapeutic Segment @

Advanced Cervical Cancer Therapeutics Landscape

There are approx. 70+ key companies developing therapies for Advanced Cervical Cancer. AstraZeneca is leading the therapeutics market with its Advanced Cervical Cancer drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Advanced Cervical Cancer Therapeutics Market Include:




Bristol-Myers Squibb

Innovent Biologics

Shanghai Henlius Biotech


Genexine, Inc.

Merck KGaA

Zeria Pharmaceutical

ISA Pharmaceuticals

Agenus Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Vaccibody AS

Fujifilm Pharmaceuticals U.S.A., Inc.


CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Xencor, Inc.

Sotio a.s.

Andes Biotechnologies

And Many Others

Advanced Cervical Cancer Therapies Covered in the Report Include:

Imfinzi (durvalumab): AstraZeneca

Dostarlimab: GlaxoSmithKline

Andes 1537: Andes Biotechnologies

PDS 0101: PDS Biotechnology Corporation

Cemiplimab: Regeneron Pharmaceuticals

DeTIL 0255: Nurix

Z-100: Zeria Pharmaceutical

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Contents

1. Report Introduction

2. Executive Summary

3. Advanced Cervical Cancer Current Treatment Patterns

4. Advanced Cervical Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Advanced Cervical Cancer Late-Stage Products (Phase-III)

7. Advanced Cervical Cancer Mid-Stage Products (Phase-II)

8. Advanced Cervical Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Advanced Cervical Cancer Discontinued Products

13. Advanced Cervical Cancer Product Profiles

14. Key Companies in the Advanced Cervical Cancer Market

15. Key Products in the Advanced Cervical Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Advanced Cervical Cancer Unmet Needs

18. Advanced Cervical Cancer Future Perspectives

19. Advanced Cervical Cancer Analyst Review

20. Appendix

21. Report Methodology

Download Sample PDF to Explore the Key Offerings of the Report:

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States